Korea Pharma Reports 19.2 Billion KRW in 3Q Sales... "Continued Portfolio Expansion"

Specialty pharmaceutical company Korea Pharma announced on the 15th that it recorded sales of 19.2 billion KRW and an operating profit of 1.1 billion KRW in the third quarter. Net profit for the same period reached 1.3 billion KRW.

Growth in third-quarter revenue was stagnant due to a reduction in product sales of external pharmaceuticals. This was because contracts were terminated and sales were halted for some products with difficult competitiveness starting early this year.

The sales gap caused by the reduction in product sales is being compensated by the launch of new specialty pharmaceuticals. This year, Korea Pharma newly launched Desvenlafaxine Extended-Release Tablets, Divalpro Extended-Release Tablets, Albix Tablets, and expanded its product portfolio. In particular, Desvenlafaxine obtained approval earlier than competitors as the first generic of Pfizer’s depression treatment Pristiq, securing market leadership.

A Korea Pharma representative stated, "Despite the overall difficulties in the pharmaceutical industry, we recorded solid performance based on a strong product portfolio focused on the central nervous system," adding, "We will strive to get back on the growth track through continuous portfolio expansion and strengthening of sales capabilities."

This content was produced with the assistance of AI translation services.